11:38 AM EDT, 09/15/2025 (MT Newswires) -- (Updates with company comment in the third paragraph.)

Hims & Hers Health ( HIMS ) faces renewed scrutiny for its Super Bowl advertisement for a weight-loss drug after US Food and Drug Administration Commissioner Martin Makary wrote in the Journal of the American Medical Association that the company violated federal regulations by highlighting the benefits of glucagon-like peptide-1 drugs without providing details on side effects,

Under the Federal Food, Drug, and Cosmetic Act, the FDA has the authority to ensure that all prescription drug ads provide a "fair balance" of risks and benefits and don't create a "misleading impression," Makary wrote in the Journal on Friday.

The Super Bowl ad "did not advertise any one treatment or solution," a Hims & Hers spokesperson said Monday in an email to MT Newswires. "Rather, it aimed to raise awareness to a critical issue -- the obesity public health crisis -- by showcasing the impact of obesity and the realities of the lack of access to life-saving holistic weight loss care."

Hims & Hers shares rose 0.2% in recent Monday trading.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 55.63, Change: +0.13, Percent Change: +0.23